May 11, 2011
Pharmacosmos A/S and Eddingpharm (Asia) Co., Ltd. has entered
into an exclusive licensing agreement for sales of CosmoFer® (low
Mw iron dextran) and Monofer® (iron isomaltoside 1000) in China.
CosmoFer® and Monofer® are developed by Pharmacosmos for treatment
of iron deficiency anemia1,2 (IDA).
With this agreement, Eddingpharm will take over sales and
promotion activities for CosmoFer® and collaborate with
Pharmacosmos on the registration of Monofer® in China.
CosmoFer® (low Mw iron dextran) is a treatment for iron
deficiency anemia that can be administrated as both intramuscular
and intravenous injection. CosmoFer® can be given in high doses as
total dose infusion (TDI) or in low doses when repetitive session
is preferred1. The product is marketed in more than 45
Monofer® (iron isomaltoside 1000) is an innovative chemical
structure for the treatment of iron deficiency anemia. Monofer® is
registered in 22 European countries and was launched in Europe in
2010. Monofer® offers low or high dose treatment of 100mg to 2000mg
in one session and in one hour.Monofer® has a good safety profile
and requires no test dose2.
It is reported that about 200 million people in China are
suffering from iron deficiency anemia and iron malnutrition. The
overall incidence rate is 15% to 20%, and children and women are
high-risk population. Serious anemia patients, especially pregnant
women, cancer patients, dialysis, transplantation and other surgery
patients, need safe, fast and efficient iron treatment. Iron
deficiency reduces production of hemoglobin, causing iron
deficiency anemia, manifested as pale, interest weakness,
palpitations, shortness of breath, dizziness, tinnitus, vertigo and
other symptoms. CosmoFer® and Monofer® are broadly indicated to
treat iron deficiency anemia.
"CosmoFer® and Monofer® will strengthen Eddingpharm's
capabilities in different therapeutic areas in the Chinese market.
Eddingpharm is committed to make further contributions to improving
quality of life for anemia patients and is excited about the new
partnership with Pharmacosmos" says Eddingpharm President
& CEO Mr. Ni Xin.
"CosmoFer® is a leading IV iron product and has a proven
efficacy and safety profile documented from use in more then 45
countries worldwide. Monofer® is an innovative agent and we expect
that both products will play a major role in the future IV iron
therapy in China," says Pharmacosmos President and CEO Mr.
Lars Christensen, "We are very excited about our new
partnership with Eddingpharm and we look forward to establish a
strong iron business in China with Eddingpharm as our
Contact for further information
T: +45 5948 5959
Business Development Department
T: +86 21 6095 6666
1) Cosmofer® Core Summary of Product
2) Monofer® Core Summary of Product
© 2010 Pharmacosmos A/S. CosmoFer® and
Monofer® is a registered trademark of Pharmacosmos A/S.
Eddingpharm is a leading specialty pharmaceutical company
operating in the rapidly growing Chinese healthcare market. Founded
in 2001, Eddingpharm has grown from a sales and marketing company
to a full commercialization service provider for multinational and
domestic pharmaceutical companies. The company focuses on
in-licensing, marketing and distribution of complementary hospital
pharmaceutical products, effectively providing a "one stop"
interface to both its suppliers as well as its customers.
Merrill Lynch invested in Eddingpharm in 2008. Orbimed, Domain
Associates and Sequoia healthcare funds invested in Eddingpharm in
About Pharmacosmos A/S
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.